ATOS

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Atossa Therapeutics announces acceptance of manuscript highlighting utrophin-modulation potential of Z-Endoxifen in Duchenne muscular dystrophyMay 21, 2026
• Atossa Therapeutics received FDA Rare Pediatric Disease designation for (Z)-Endoxifen in McCune-Albright syndromeMay 4, 2026
• Atossa Therapeutics maintained a strong market position for (Z)-Endoxifen in Duchenne muscular dystrophy as Congress reauthorized the priority review voucher programFeb 5, 2026
• Atossa Therapeutics receives FDA rare pediatric disease designation for (Z)-Endoxifen in Duchenne muscular dystrophyDec 11, 2025
• Atossa Therapeutics details accelerated FDA strategy for (Z)-Endoxifen across breast cancer continuumDec 4, 2025